The antitumor effects of BET-i have been shown to, at least partially, rely on T cell presence in other malignancies (55, 56); however, experiments using T cell–deficient CLL models are needed to decipher the therapeutic effect of improved T cell function with OPN5 treatment in this setting. The gene discussed is OPN5; the disease is B-cell chronic lymphocytic leukemia.